Monte Rosa Therapeutics
GLUE
GLUE
74 hedge funds and large institutions have $171M invested in Monte Rosa Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
4.59% less ownership
Funds ownership: 79.55% → 74.96% (-4.6%)
39% less capital invested
Capital invested by funds: $281M → $171M (-$110M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
74
Holding in Top 10
1
Calls
$374K
Puts
$89K
Top Buyers
| 1 | +$9.94M | |
| 2 | +$3.41M | |
| 3 | +$3.33M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.29M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.4M |
Top Sellers
| 1 | -$935K | |
| 2 | -$919K | |
| 3 | -$483K | |
| 4 |
EC
EntryPoint Capital
New York
|
-$112K |
| 5 |
AIG
American International Group
New York
|
-$107K |